SNES vs. LGVN, ENSC, PEAR, ARTL, SNGX, TCON, XCUR, THAR, VERO, and NIVF
Should you be buying SenesTech stock or one of its competitors? The main competitors of SenesTech include Longeveron (LGVN), Ensysce Biosciences (ENSC), Pear Therapeutics (PEAR), Artelo Biosciences (ARTL), Soligenix (SNGX), TRACON Pharmaceuticals (TCON), Exicure (XCUR), Tharimmune (THAR), Venus Concept (VERO), and NewGenIvf Group (NIVF). These companies are all part of the "medical" sector.
SenesTech (NASDAQ:SNES) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, community ranking, media sentiment, institutional ownership and valuation.
In the previous week, SenesTech had 6 more articles in the media than Longeveron. MarketBeat recorded 10 mentions for SenesTech and 4 mentions for Longeveron. Longeveron's average media sentiment score of 0.72 beat SenesTech's score of -0.05 indicating that Longeveron is being referred to more favorably in the news media.
SenesTech has higher revenue and earnings than Longeveron.
SenesTech has a net margin of -545.82% compared to Longeveron's net margin of -3,020.17%. SenesTech's return on equity of -181.46% beat Longeveron's return on equity.
SenesTech has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
SenesTech currently has a consensus price target of $3.50, indicating a potential upside of 373.68%. Longeveron has a consensus price target of $12.00, indicating a potential upside of 775.91%. Given Longeveron's higher possible upside, analysts clearly believe Longeveron is more favorable than SenesTech.
5.2% of SenesTech shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 5.3% of SenesTech shares are owned by company insiders. Comparatively, 24.3% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
SenesTech received 313 more outperform votes than Longeveron when rated by MarketBeat users. However, 87.50% of users gave Longeveron an outperform vote while only 65.17% of users gave SenesTech an outperform vote.
Summary
SenesTech and Longeveron tied by winning 7 of the 14 factors compared between the two stocks.
Get SenesTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNES and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNES and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SenesTech Competitors List
Related Companies and Tools
